Mass treatment to eliminate tuberculosis from an island population.
Identifieur interne : 003407 ( PubMed/Checkpoint ); précédent : 003406; suivant : 003408Mass treatment to eliminate tuberculosis from an island population.
Auteurs : P C Hill [Nouvelle-Zélande] ; C. Dye [Suisse] ; K. Viney ; K. Tabutoa ; T. Kienene ; K. Bissell [France] ; B G Williams [Afrique du Sud] ; R. Zachariah [Belgique] ; B J Marais [Australie] ; A D Harries [France]Source :
- The international journal of tuberculosis and lung disease : the official journal of the International Union against Tuberculosis and Lung Disease [ 1815-7920 ] ; 2014.
Descripteurs français
- KwdFr :
- Adolescent, Adulte, Adulte d'âge moyen, Antituberculeux (administration et posologie), Antituberculeux (usage thérapeutique), Enfant, Enfant d'âge préscolaire, Facteurs temps, Femelle, Humains, Incidence, Jeune adulte, Micronésie (épidémiologie), Modèles théoriques, Mycobacterium tuberculosis (pathogénicité), Mâle, Nourrisson, Récidive, Sujet âgé, Tuberculose (), Tuberculose (microbiologie), Tuberculose (épidémiologie), Tuberculose latente (microbiologie), Tuberculose latente (traitement médicamenteux), Tuberculose latente (épidémiologie), Évolution de la maladie.
- MESH :
- administration et posologie : Antituberculeux.
- microbiologie : Tuberculose, Tuberculose latente.
- pathogénicité : Mycobacterium tuberculosis.
- traitement médicamenteux : Tuberculose latente.
- usage thérapeutique : Antituberculeux.
- épidémiologie : Micronésie, Tuberculose, Tuberculose latente.
- Adolescent, Adulte, Adulte d'âge moyen, Enfant, Enfant d'âge préscolaire, Facteurs temps, Femelle, Humains, Incidence, Jeune adulte, Modèles théoriques, Mâle, Nourrisson, Récidive, Sujet âgé, Tuberculose, Évolution de la maladie.
English descriptors
- KwdEn :
- Adolescent, Adult, Aged, Antitubercular Agents (administration & dosage), Antitubercular Agents (therapeutic use), Child, Child, Preschool, Disease Progression, Female, Humans, Incidence, Infant, Latent Tuberculosis (drug therapy), Latent Tuberculosis (epidemiology), Latent Tuberculosis (microbiology), Male, Micronesia (epidemiology), Middle Aged, Models, Theoretical, Mycobacterium tuberculosis (pathogenicity), Recurrence, Time Factors, Tuberculosis (epidemiology), Tuberculosis (microbiology), Tuberculosis (prevention & control), Young Adult.
- MESH :
- chemical , administration & dosage : Antitubercular Agents.
- chemical , therapeutic use : Antitubercular Agents.
- geographic , epidemiology : Micronesia.
- drug therapy : Latent Tuberculosis.
- epidemiology : Latent Tuberculosis, Tuberculosis.
- microbiology : Latent Tuberculosis, Tuberculosis.
- pathogenicity : Mycobacterium tuberculosis.
- prevention & control : Tuberculosis.
- Adolescent, Adult, Aged, Child, Child, Preschool, Disease Progression, Female, Humans, Incidence, Infant, Male, Middle Aged, Models, Theoretical, Recurrence, Time Factors, Young Adult.
Abstract
The global target of tuberculosis (TB) elimination by 2050 requires new approaches. Active case finding plus mass prophylactic treatment has been disappointing. We consider mass full anti-tuberculosis treatment as an approach to TB elimination in Kiribati, a Pacific Island nation, with a persistent epidemic of high TB incidence.
DOI: 10.5588/ijtld.14.0007
PubMed: 25199002
Affiliations:
- Afrique du Sud, Australie, Belgique, France, Nouvelle-Zélande, Suisse
- Nouvelle-Galles du Sud, Île-de-France
- Paris, Sydney
- Université de Sydney
Links toward previous steps (curation, corpus...)
Links to Exploration step
pubmed:25199002Le document en format XML
<record><TEI><teiHeader><fileDesc><titleStmt><title xml:lang="en">Mass treatment to eliminate tuberculosis from an island population.</title>
<author><name sortKey="Hill, P C" sort="Hill, P C" uniqKey="Hill P" first="P C" last="Hill">P C Hill</name>
<affiliation wicri:level="1"><nlm:affiliation>Centre for International Health, Department of Preventive and Social Medicine, Faculty of Medicine, University of Otago, Dunedin, New Zealand;</nlm:affiliation>
<country xml:lang="fr">Nouvelle-Zélande</country>
<wicri:regionArea>Centre for International Health, Department of Preventive and Social Medicine, Faculty of Medicine, University of Otago, Dunedin</wicri:regionArea>
<wicri:noRegion>Dunedin</wicri:noRegion>
</affiliation>
</author>
<author><name sortKey="Dye, C" sort="Dye, C" uniqKey="Dye C" first="C" last="Dye">C. Dye</name>
<affiliation wicri:level="1"><nlm:affiliation>HIV/AIDS, Tuberculosis, Malaria & Neglected Tropical Diseases Cluster, World Health Organization, Geneva, Switzerland;</nlm:affiliation>
<country xml:lang="fr">Suisse</country>
<wicri:regionArea>HIV/AIDS, Tuberculosis, Malaria & Neglected Tropical Diseases Cluster, World Health Organization, Geneva</wicri:regionArea>
<wicri:noRegion>Geneva</wicri:noRegion>
</affiliation>
</author>
<author><name sortKey="Viney, K" sort="Viney, K" uniqKey="Viney K" first="K" last="Viney">K. Viney</name>
<affiliation><nlm:affiliation>Public Health Division, Secretariat of the Pacific Community, Noumea Cedex, New Caledonia;</nlm:affiliation>
<wicri:noCountry code="subField">New Caledonia</wicri:noCountry>
</affiliation>
</author>
<author><name sortKey="Tabutoa, K" sort="Tabutoa, K" uniqKey="Tabutoa K" first="K" last="Tabutoa">K. Tabutoa</name>
<affiliation><nlm:affiliation>National Tuberculosis Control Programme, Ministry of Health and Medical Services, Republic of Kiribati;</nlm:affiliation>
<wicri:noCountry code="subField">Republic of Kiribati</wicri:noCountry>
</affiliation>
</author>
<author><name sortKey="Kienene, T" sort="Kienene, T" uniqKey="Kienene T" first="T" last="Kienene">T. Kienene</name>
<affiliation><nlm:affiliation>National Tuberculosis Control Programme, Ministry of Health and Medical Services, Republic of Kiribati;</nlm:affiliation>
<wicri:noCountry code="subField">Republic of Kiribati</wicri:noCountry>
</affiliation>
</author>
<author><name sortKey="Bissell, K" sort="Bissell, K" uniqKey="Bissell K" first="K" last="Bissell">K. Bissell</name>
<affiliation wicri:level="3"><nlm:affiliation>International Union Against Tuberculosis and Lung Disease, Paris, France;</nlm:affiliation>
<country xml:lang="fr">France</country>
<wicri:regionArea>International Union Against Tuberculosis and Lung Disease, Paris</wicri:regionArea>
<placeName><region type="region">Île-de-France</region>
<region type="old region">Île-de-France</region>
<settlement type="city">Paris</settlement>
</placeName>
</affiliation>
</author>
<author><name sortKey="Williams, B G" sort="Williams, B G" uniqKey="Williams B" first="B G" last="Williams">B G Williams</name>
<affiliation wicri:level="1"><nlm:affiliation>*South African Centre for Epidemiological Modelling and Analysis, Cape Town, South Africa;</nlm:affiliation>
<country xml:lang="fr">Afrique du Sud</country>
<wicri:regionArea>*South African Centre for Epidemiological Modelling and Analysis, Cape Town</wicri:regionArea>
<wicri:noRegion>Cape Town</wicri:noRegion>
</affiliation>
</author>
<author><name sortKey="Zachariah, R" sort="Zachariah, R" uniqKey="Zachariah R" first="R" last="Zachariah">R. Zachariah</name>
<affiliation wicri:level="1"><nlm:affiliation>Médecins Sans Frontières, Brussels Operational Centre, Luxembourg, Belgium;</nlm:affiliation>
<country xml:lang="fr">Belgique</country>
<wicri:regionArea>Médecins Sans Frontières, Brussels Operational Centre, Luxembourg</wicri:regionArea>
<wicri:noRegion>Luxembourg</wicri:noRegion>
</affiliation>
</author>
<author><name sortKey="Marais, B J" sort="Marais, B J" uniqKey="Marais B" first="B J" last="Marais">B J Marais</name>
<affiliation wicri:level="4"><nlm:affiliation>Sydney Emerging Infectious Disease and Biosecurity Institute and Centre for Research Excellence in Tuberculosis, University of Sydney, Sydney, New South Wales, Australia;</nlm:affiliation>
<country xml:lang="fr">Australie</country>
<wicri:regionArea>Sydney Emerging Infectious Disease and Biosecurity Institute and Centre for Research Excellence in Tuberculosis, University of Sydney, Sydney, New South Wales</wicri:regionArea>
<orgName type="university">Université de Sydney</orgName>
<placeName><settlement type="city">Sydney</settlement>
<region type="état">Nouvelle-Galles du Sud</region>
</placeName>
</affiliation>
</author>
<author><name sortKey="Harries, A D" sort="Harries, A D" uniqKey="Harries A" first="A D" last="Harries">A D Harries</name>
<affiliation wicri:level="3"><nlm:affiliation>International Union Against Tuberculosis and Lung Disease, Paris, France;</nlm:affiliation>
<country xml:lang="fr">France</country>
<wicri:regionArea>International Union Against Tuberculosis and Lung Disease, Paris</wicri:regionArea>
<placeName><region type="region">Île-de-France</region>
<region type="old region">Île-de-France</region>
<settlement type="city">Paris</settlement>
</placeName>
</affiliation>
</author>
</titleStmt>
<publicationStmt><idno type="wicri:source">PubMed</idno>
<date when="2014">2014</date>
<idno type="RBID">pubmed:25199002</idno>
<idno type="pmid">25199002</idno>
<idno type="doi">10.5588/ijtld.14.0007</idno>
<idno type="wicri:Area/PubMed/Corpus">003551</idno>
<idno type="wicri:explorRef" wicri:stream="PubMed" wicri:step="Corpus" wicri:corpus="PubMed">003551</idno>
<idno type="wicri:Area/PubMed/Curation">003438</idno>
<idno type="wicri:explorRef" wicri:stream="PubMed" wicri:step="Curation">003438</idno>
<idno type="wicri:Area/PubMed/Checkpoint">003438</idno>
<idno type="wicri:explorRef" wicri:stream="Checkpoint" wicri:step="PubMed">003438</idno>
</publicationStmt>
<sourceDesc><biblStruct><analytic><title xml:lang="en">Mass treatment to eliminate tuberculosis from an island population.</title>
<author><name sortKey="Hill, P C" sort="Hill, P C" uniqKey="Hill P" first="P C" last="Hill">P C Hill</name>
<affiliation wicri:level="1"><nlm:affiliation>Centre for International Health, Department of Preventive and Social Medicine, Faculty of Medicine, University of Otago, Dunedin, New Zealand;</nlm:affiliation>
<country xml:lang="fr">Nouvelle-Zélande</country>
<wicri:regionArea>Centre for International Health, Department of Preventive and Social Medicine, Faculty of Medicine, University of Otago, Dunedin</wicri:regionArea>
<wicri:noRegion>Dunedin</wicri:noRegion>
</affiliation>
</author>
<author><name sortKey="Dye, C" sort="Dye, C" uniqKey="Dye C" first="C" last="Dye">C. Dye</name>
<affiliation wicri:level="1"><nlm:affiliation>HIV/AIDS, Tuberculosis, Malaria & Neglected Tropical Diseases Cluster, World Health Organization, Geneva, Switzerland;</nlm:affiliation>
<country xml:lang="fr">Suisse</country>
<wicri:regionArea>HIV/AIDS, Tuberculosis, Malaria & Neglected Tropical Diseases Cluster, World Health Organization, Geneva</wicri:regionArea>
<wicri:noRegion>Geneva</wicri:noRegion>
</affiliation>
</author>
<author><name sortKey="Viney, K" sort="Viney, K" uniqKey="Viney K" first="K" last="Viney">K. Viney</name>
<affiliation><nlm:affiliation>Public Health Division, Secretariat of the Pacific Community, Noumea Cedex, New Caledonia;</nlm:affiliation>
<wicri:noCountry code="subField">New Caledonia</wicri:noCountry>
</affiliation>
</author>
<author><name sortKey="Tabutoa, K" sort="Tabutoa, K" uniqKey="Tabutoa K" first="K" last="Tabutoa">K. Tabutoa</name>
<affiliation><nlm:affiliation>National Tuberculosis Control Programme, Ministry of Health and Medical Services, Republic of Kiribati;</nlm:affiliation>
<wicri:noCountry code="subField">Republic of Kiribati</wicri:noCountry>
</affiliation>
</author>
<author><name sortKey="Kienene, T" sort="Kienene, T" uniqKey="Kienene T" first="T" last="Kienene">T. Kienene</name>
<affiliation><nlm:affiliation>National Tuberculosis Control Programme, Ministry of Health and Medical Services, Republic of Kiribati;</nlm:affiliation>
<wicri:noCountry code="subField">Republic of Kiribati</wicri:noCountry>
</affiliation>
</author>
<author><name sortKey="Bissell, K" sort="Bissell, K" uniqKey="Bissell K" first="K" last="Bissell">K. Bissell</name>
<affiliation wicri:level="3"><nlm:affiliation>International Union Against Tuberculosis and Lung Disease, Paris, France;</nlm:affiliation>
<country xml:lang="fr">France</country>
<wicri:regionArea>International Union Against Tuberculosis and Lung Disease, Paris</wicri:regionArea>
<placeName><region type="region">Île-de-France</region>
<region type="old region">Île-de-France</region>
<settlement type="city">Paris</settlement>
</placeName>
</affiliation>
</author>
<author><name sortKey="Williams, B G" sort="Williams, B G" uniqKey="Williams B" first="B G" last="Williams">B G Williams</name>
<affiliation wicri:level="1"><nlm:affiliation>*South African Centre for Epidemiological Modelling and Analysis, Cape Town, South Africa;</nlm:affiliation>
<country xml:lang="fr">Afrique du Sud</country>
<wicri:regionArea>*South African Centre for Epidemiological Modelling and Analysis, Cape Town</wicri:regionArea>
<wicri:noRegion>Cape Town</wicri:noRegion>
</affiliation>
</author>
<author><name sortKey="Zachariah, R" sort="Zachariah, R" uniqKey="Zachariah R" first="R" last="Zachariah">R. Zachariah</name>
<affiliation wicri:level="1"><nlm:affiliation>Médecins Sans Frontières, Brussels Operational Centre, Luxembourg, Belgium;</nlm:affiliation>
<country xml:lang="fr">Belgique</country>
<wicri:regionArea>Médecins Sans Frontières, Brussels Operational Centre, Luxembourg</wicri:regionArea>
<wicri:noRegion>Luxembourg</wicri:noRegion>
</affiliation>
</author>
<author><name sortKey="Marais, B J" sort="Marais, B J" uniqKey="Marais B" first="B J" last="Marais">B J Marais</name>
<affiliation wicri:level="4"><nlm:affiliation>Sydney Emerging Infectious Disease and Biosecurity Institute and Centre for Research Excellence in Tuberculosis, University of Sydney, Sydney, New South Wales, Australia;</nlm:affiliation>
<country xml:lang="fr">Australie</country>
<wicri:regionArea>Sydney Emerging Infectious Disease and Biosecurity Institute and Centre for Research Excellence in Tuberculosis, University of Sydney, Sydney, New South Wales</wicri:regionArea>
<orgName type="university">Université de Sydney</orgName>
<placeName><settlement type="city">Sydney</settlement>
<region type="état">Nouvelle-Galles du Sud</region>
</placeName>
</affiliation>
</author>
<author><name sortKey="Harries, A D" sort="Harries, A D" uniqKey="Harries A" first="A D" last="Harries">A D Harries</name>
<affiliation wicri:level="3"><nlm:affiliation>International Union Against Tuberculosis and Lung Disease, Paris, France;</nlm:affiliation>
<country xml:lang="fr">France</country>
<wicri:regionArea>International Union Against Tuberculosis and Lung Disease, Paris</wicri:regionArea>
<placeName><region type="region">Île-de-France</region>
<region type="old region">Île-de-France</region>
<settlement type="city">Paris</settlement>
</placeName>
</affiliation>
</author>
</analytic>
<series><title level="j">The international journal of tuberculosis and lung disease : the official journal of the International Union against Tuberculosis and Lung Disease</title>
<idno type="eISSN">1815-7920</idno>
<imprint><date when="2014" type="published">2014</date>
</imprint>
</series>
</biblStruct>
</sourceDesc>
</fileDesc>
<profileDesc><textClass><keywords scheme="KwdEn" xml:lang="en"><term>Adolescent</term>
<term>Adult</term>
<term>Aged</term>
<term>Antitubercular Agents (administration & dosage)</term>
<term>Antitubercular Agents (therapeutic use)</term>
<term>Child</term>
<term>Child, Preschool</term>
<term>Disease Progression</term>
<term>Female</term>
<term>Humans</term>
<term>Incidence</term>
<term>Infant</term>
<term>Latent Tuberculosis (drug therapy)</term>
<term>Latent Tuberculosis (epidemiology)</term>
<term>Latent Tuberculosis (microbiology)</term>
<term>Male</term>
<term>Micronesia (epidemiology)</term>
<term>Middle Aged</term>
<term>Models, Theoretical</term>
<term>Mycobacterium tuberculosis (pathogenicity)</term>
<term>Recurrence</term>
<term>Time Factors</term>
<term>Tuberculosis (epidemiology)</term>
<term>Tuberculosis (microbiology)</term>
<term>Tuberculosis (prevention & control)</term>
<term>Young Adult</term>
</keywords>
<keywords scheme="KwdFr" xml:lang="fr"><term>Adolescent</term>
<term>Adulte</term>
<term>Adulte d'âge moyen</term>
<term>Antituberculeux (administration et posologie)</term>
<term>Antituberculeux (usage thérapeutique)</term>
<term>Enfant</term>
<term>Enfant d'âge préscolaire</term>
<term>Facteurs temps</term>
<term>Femelle</term>
<term>Humains</term>
<term>Incidence</term>
<term>Jeune adulte</term>
<term>Micronésie (épidémiologie)</term>
<term>Modèles théoriques</term>
<term>Mycobacterium tuberculosis (pathogénicité)</term>
<term>Mâle</term>
<term>Nourrisson</term>
<term>Récidive</term>
<term>Sujet âgé</term>
<term>Tuberculose ()</term>
<term>Tuberculose (microbiologie)</term>
<term>Tuberculose (épidémiologie)</term>
<term>Tuberculose latente (microbiologie)</term>
<term>Tuberculose latente (traitement médicamenteux)</term>
<term>Tuberculose latente (épidémiologie)</term>
<term>Évolution de la maladie</term>
</keywords>
<keywords scheme="MESH" type="chemical" qualifier="administration & dosage" xml:lang="en"><term>Antitubercular Agents</term>
</keywords>
<keywords scheme="MESH" type="chemical" qualifier="therapeutic use" xml:lang="en"><term>Antitubercular Agents</term>
</keywords>
<keywords scheme="MESH" type="geographic" qualifier="epidemiology" xml:lang="en"><term>Micronesia</term>
</keywords>
<keywords scheme="MESH" qualifier="administration et posologie" xml:lang="fr"><term>Antituberculeux</term>
</keywords>
<keywords scheme="MESH" qualifier="drug therapy" xml:lang="en"><term>Latent Tuberculosis</term>
</keywords>
<keywords scheme="MESH" qualifier="epidemiology" xml:lang="en"><term>Latent Tuberculosis</term>
<term>Tuberculosis</term>
</keywords>
<keywords scheme="MESH" qualifier="microbiologie" xml:lang="fr"><term>Tuberculose</term>
<term>Tuberculose latente</term>
</keywords>
<keywords scheme="MESH" qualifier="microbiology" xml:lang="en"><term>Latent Tuberculosis</term>
<term>Tuberculosis</term>
</keywords>
<keywords scheme="MESH" qualifier="pathogenicity" xml:lang="en"><term>Mycobacterium tuberculosis</term>
</keywords>
<keywords scheme="MESH" qualifier="pathogénicité" xml:lang="fr"><term>Mycobacterium tuberculosis</term>
</keywords>
<keywords scheme="MESH" qualifier="prevention & control" xml:lang="en"><term>Tuberculosis</term>
</keywords>
<keywords scheme="MESH" qualifier="traitement médicamenteux" xml:lang="fr"><term>Tuberculose latente</term>
</keywords>
<keywords scheme="MESH" qualifier="usage thérapeutique" xml:lang="fr"><term>Antituberculeux</term>
</keywords>
<keywords scheme="MESH" qualifier="épidémiologie" xml:lang="fr"><term>Micronésie</term>
<term>Tuberculose</term>
<term>Tuberculose latente</term>
</keywords>
<keywords scheme="MESH" xml:lang="en"><term>Adolescent</term>
<term>Adult</term>
<term>Aged</term>
<term>Child</term>
<term>Child, Preschool</term>
<term>Disease Progression</term>
<term>Female</term>
<term>Humans</term>
<term>Incidence</term>
<term>Infant</term>
<term>Male</term>
<term>Middle Aged</term>
<term>Models, Theoretical</term>
<term>Recurrence</term>
<term>Time Factors</term>
<term>Young Adult</term>
</keywords>
<keywords scheme="MESH" xml:lang="fr"><term>Adolescent</term>
<term>Adulte</term>
<term>Adulte d'âge moyen</term>
<term>Enfant</term>
<term>Enfant d'âge préscolaire</term>
<term>Facteurs temps</term>
<term>Femelle</term>
<term>Humains</term>
<term>Incidence</term>
<term>Jeune adulte</term>
<term>Modèles théoriques</term>
<term>Mâle</term>
<term>Nourrisson</term>
<term>Récidive</term>
<term>Sujet âgé</term>
<term>Tuberculose</term>
<term>Évolution de la maladie</term>
</keywords>
</textClass>
</profileDesc>
</teiHeader>
<front><div type="abstract" xml:lang="en">The global target of tuberculosis (TB) elimination by 2050 requires new approaches. Active case finding plus mass prophylactic treatment has been disappointing. We consider mass full anti-tuberculosis treatment as an approach to TB elimination in Kiribati, a Pacific Island nation, with a persistent epidemic of high TB incidence.</div>
</front>
</TEI>
<pubmed><MedlineCitation Status="MEDLINE" Owner="NLM"><PMID Version="1">25199002</PMID>
<DateCreated><Year>2014</Year>
<Month>09</Month>
<Day>09</Day>
</DateCreated>
<DateCompleted><Year>2015</Year>
<Month>05</Month>
<Day>21</Day>
</DateCompleted>
<DateRevised><Year>2017</Year>
<Month>09</Month>
<Day>22</Day>
</DateRevised>
<Article PubModel="Print"><Journal><ISSN IssnType="Electronic">1815-7920</ISSN>
<JournalIssue CitedMedium="Internet"><Volume>18</Volume>
<Issue>8</Issue>
<PubDate><Year>2014</Year>
<Month>Aug</Month>
</PubDate>
</JournalIssue>
<Title>The international journal of tuberculosis and lung disease : the official journal of the International Union against Tuberculosis and Lung Disease</Title>
<ISOAbbreviation>Int. J. Tuberc. Lung Dis.</ISOAbbreviation>
</Journal>
<ArticleTitle>Mass treatment to eliminate tuberculosis from an island population.</ArticleTitle>
<Pagination><MedlinePgn>899-904</MedlinePgn>
</Pagination>
<ELocationID EIdType="doi" ValidYN="Y">10.5588/ijtld.14.0007</ELocationID>
<Abstract><AbstractText Label="SETTING" NlmCategory="METHODS">The global target of tuberculosis (TB) elimination by 2050 requires new approaches. Active case finding plus mass prophylactic treatment has been disappointing. We consider mass full anti-tuberculosis treatment as an approach to TB elimination in Kiribati, a Pacific Island nation, with a persistent epidemic of high TB incidence.</AbstractText>
<AbstractText Label="OBJECTIVE" NlmCategory="OBJECTIVE">To construct a mathematical model to predict whether mass treatment with a full course of anti-tuberculosis drugs might eliminate TB from the defined population of the Republic of Kiribati.</AbstractText>
<AbstractText Label="METHODS" NlmCategory="METHODS">We constructed a seven-state compartmental model of the life cycle of Mycobacterium tuberculosis in which active TB disease arises from the progression of infection, reinfection, reactivation and relapse, while distinguishing infectious from non-infectious disease. We evaluated the effects of 5-yearly mass treatment using a range of parameter values to generate outcomes in uncertainty analysis.</AbstractText>
<AbstractText Label="RESULTS" NlmCategory="RESULTS">Assuming population-wide treatment effectiveness for latent tuberculous infection and active TB of ⩾90%, annual TB incidence is expected to fall sharply at each 5-yearly round of treatment, approaching elimination in two decades. The model showed that the incidence rate is sensitive to the relapse rate after successful treatment of TB.</AbstractText>
<AbstractText Label="CONCLUSION" NlmCategory="CONCLUSIONS">Mass treatment may help to eliminate TB, at least for discrete or geographically isolated populations.</AbstractText>
</Abstract>
<AuthorList CompleteYN="Y"><Author ValidYN="Y"><LastName>Hill</LastName>
<ForeName>P C</ForeName>
<Initials>PC</Initials>
<AffiliationInfo><Affiliation>Centre for International Health, Department of Preventive and Social Medicine, Faculty of Medicine, University of Otago, Dunedin, New Zealand;</Affiliation>
</AffiliationInfo>
</Author>
<Author ValidYN="Y"><LastName>Dye</LastName>
<ForeName>C</ForeName>
<Initials>C</Initials>
<AffiliationInfo><Affiliation>HIV/AIDS, Tuberculosis, Malaria & Neglected Tropical Diseases Cluster, World Health Organization, Geneva, Switzerland;</Affiliation>
</AffiliationInfo>
</Author>
<Author ValidYN="Y"><LastName>Viney</LastName>
<ForeName>K</ForeName>
<Initials>K</Initials>
<AffiliationInfo><Affiliation>Public Health Division, Secretariat of the Pacific Community, Noumea Cedex, New Caledonia;</Affiliation>
</AffiliationInfo>
</Author>
<Author ValidYN="Y"><LastName>Tabutoa</LastName>
<ForeName>K</ForeName>
<Initials>K</Initials>
<AffiliationInfo><Affiliation>National Tuberculosis Control Programme, Ministry of Health and Medical Services, Republic of Kiribati;</Affiliation>
</AffiliationInfo>
</Author>
<Author ValidYN="Y"><LastName>Kienene</LastName>
<ForeName>T</ForeName>
<Initials>T</Initials>
<AffiliationInfo><Affiliation>National Tuberculosis Control Programme, Ministry of Health and Medical Services, Republic of Kiribati;</Affiliation>
</AffiliationInfo>
</Author>
<Author ValidYN="Y"><LastName>Bissell</LastName>
<ForeName>K</ForeName>
<Initials>K</Initials>
<AffiliationInfo><Affiliation>International Union Against Tuberculosis and Lung Disease, Paris, France;</Affiliation>
</AffiliationInfo>
</Author>
<Author ValidYN="Y"><LastName>Williams</LastName>
<ForeName>B G</ForeName>
<Initials>BG</Initials>
<AffiliationInfo><Affiliation>*South African Centre for Epidemiological Modelling and Analysis, Cape Town, South Africa;</Affiliation>
</AffiliationInfo>
</Author>
<Author ValidYN="Y"><LastName>Zachariah</LastName>
<ForeName>R</ForeName>
<Initials>R</Initials>
<AffiliationInfo><Affiliation>Médecins Sans Frontières, Brussels Operational Centre, Luxembourg, Belgium;</Affiliation>
</AffiliationInfo>
</Author>
<Author ValidYN="Y"><LastName>Marais</LastName>
<ForeName>B J</ForeName>
<Initials>BJ</Initials>
<AffiliationInfo><Affiliation>Sydney Emerging Infectious Disease and Biosecurity Institute and Centre for Research Excellence in Tuberculosis, University of Sydney, Sydney, New South Wales, Australia;</Affiliation>
</AffiliationInfo>
</Author>
<Author ValidYN="Y"><LastName>Harries</LastName>
<ForeName>A D</ForeName>
<Initials>AD</Initials>
<AffiliationInfo><Affiliation>International Union Against Tuberculosis and Lung Disease, Paris, France;</Affiliation>
</AffiliationInfo>
</Author>
</AuthorList>
<Language>eng</Language>
<GrantList CompleteYN="Y"><Grant><GrantID>001</GrantID>
<Agency>World Health Organization</Agency>
<Country>International</Country>
</Grant>
</GrantList>
<PublicationTypeList><PublicationType UI="D016428">Journal Article</PublicationType>
</PublicationTypeList>
</Article>
<MedlineJournalInfo><Country>France</Country>
<MedlineTA>Int J Tuberc Lung Dis</MedlineTA>
<NlmUniqueID>9706389</NlmUniqueID>
<ISSNLinking>1027-3719</ISSNLinking>
</MedlineJournalInfo>
<ChemicalList><Chemical><RegistryNumber>0</RegistryNumber>
<NameOfSubstance UI="D000995">Antitubercular Agents</NameOfSubstance>
</Chemical>
</ChemicalList>
<CitationSubset>IM</CitationSubset>
<CommentsCorrectionsList><CommentsCorrections RefType="CommentIn"><RefSource>Int J Tuberc Lung Dis. 2014 Aug;18(8):883</RefSource>
<PMID Version="1">25198998</PMID>
</CommentsCorrections>
</CommentsCorrectionsList>
<MeshHeadingList><MeshHeading><DescriptorName UI="D000293" MajorTopicYN="N">Adolescent</DescriptorName>
</MeshHeading>
<MeshHeading><DescriptorName UI="D000328" MajorTopicYN="N">Adult</DescriptorName>
</MeshHeading>
<MeshHeading><DescriptorName UI="D000368" MajorTopicYN="N">Aged</DescriptorName>
</MeshHeading>
<MeshHeading><DescriptorName UI="D000995" MajorTopicYN="N">Antitubercular Agents</DescriptorName>
<QualifierName UI="Q000008" MajorTopicYN="N">administration & dosage</QualifierName>
<QualifierName UI="Q000627" MajorTopicYN="Y">therapeutic use</QualifierName>
</MeshHeading>
<MeshHeading><DescriptorName UI="D002648" MajorTopicYN="N">Child</DescriptorName>
</MeshHeading>
<MeshHeading><DescriptorName UI="D002675" MajorTopicYN="N">Child, Preschool</DescriptorName>
</MeshHeading>
<MeshHeading><DescriptorName UI="D018450" MajorTopicYN="N">Disease Progression</DescriptorName>
</MeshHeading>
<MeshHeading><DescriptorName UI="D005260" MajorTopicYN="N">Female</DescriptorName>
</MeshHeading>
<MeshHeading><DescriptorName UI="D006801" MajorTopicYN="N">Humans</DescriptorName>
</MeshHeading>
<MeshHeading><DescriptorName UI="D015994" MajorTopicYN="N">Incidence</DescriptorName>
</MeshHeading>
<MeshHeading><DescriptorName UI="D007223" MajorTopicYN="N">Infant</DescriptorName>
</MeshHeading>
<MeshHeading><DescriptorName UI="D055985" MajorTopicYN="N">Latent Tuberculosis</DescriptorName>
<QualifierName UI="Q000188" MajorTopicYN="N">drug therapy</QualifierName>
<QualifierName UI="Q000453" MajorTopicYN="N">epidemiology</QualifierName>
<QualifierName UI="Q000382" MajorTopicYN="N">microbiology</QualifierName>
</MeshHeading>
<MeshHeading><DescriptorName UI="D008297" MajorTopicYN="N">Male</DescriptorName>
</MeshHeading>
<MeshHeading><DescriptorName UI="D008849" MajorTopicYN="N" Type="Geographic">Micronesia</DescriptorName>
<QualifierName UI="Q000453" MajorTopicYN="N">epidemiology</QualifierName>
</MeshHeading>
<MeshHeading><DescriptorName UI="D008875" MajorTopicYN="N">Middle Aged</DescriptorName>
</MeshHeading>
<MeshHeading><DescriptorName UI="D008962" MajorTopicYN="Y">Models, Theoretical</DescriptorName>
</MeshHeading>
<MeshHeading><DescriptorName UI="D009169" MajorTopicYN="N">Mycobacterium tuberculosis</DescriptorName>
<QualifierName UI="Q000472" MajorTopicYN="Y">pathogenicity</QualifierName>
</MeshHeading>
<MeshHeading><DescriptorName UI="D012008" MajorTopicYN="N">Recurrence</DescriptorName>
</MeshHeading>
<MeshHeading><DescriptorName UI="D013997" MajorTopicYN="N">Time Factors</DescriptorName>
</MeshHeading>
<MeshHeading><DescriptorName UI="D014376" MajorTopicYN="N">Tuberculosis</DescriptorName>
<QualifierName UI="Q000453" MajorTopicYN="N">epidemiology</QualifierName>
<QualifierName UI="Q000382" MajorTopicYN="N">microbiology</QualifierName>
<QualifierName UI="Q000517" MajorTopicYN="Y">prevention & control</QualifierName>
</MeshHeading>
<MeshHeading><DescriptorName UI="D055815" MajorTopicYN="N">Young Adult</DescriptorName>
</MeshHeading>
</MeshHeadingList>
</MedlineCitation>
<PubmedData><History><PubMedPubDate PubStatus="entrez"><Year>2014</Year>
<Month>9</Month>
<Day>9</Day>
<Hour>6</Hour>
<Minute>0</Minute>
</PubMedPubDate>
<PubMedPubDate PubStatus="pubmed"><Year>2014</Year>
<Month>9</Month>
<Day>10</Day>
<Hour>6</Hour>
<Minute>0</Minute>
</PubMedPubDate>
<PubMedPubDate PubStatus="medline"><Year>2015</Year>
<Month>5</Month>
<Day>23</Day>
<Hour>6</Hour>
<Minute>0</Minute>
</PubMedPubDate>
</History>
<PublicationStatus>ppublish</PublicationStatus>
<ArticleIdList><ArticleId IdType="pubmed">25199002</ArticleId>
<ArticleId IdType="doi">10.5588/ijtld.14.0007</ArticleId>
</ArticleIdList>
</PubmedData>
</pubmed>
<affiliations><list><country><li>Afrique du Sud</li>
<li>Australie</li>
<li>Belgique</li>
<li>France</li>
<li>Nouvelle-Zélande</li>
<li>Suisse</li>
</country>
<region><li>Nouvelle-Galles du Sud</li>
<li>Île-de-France</li>
</region>
<settlement><li>Paris</li>
<li>Sydney</li>
</settlement>
<orgName><li>Université de Sydney</li>
</orgName>
</list>
<tree><noCountry><name sortKey="Kienene, T" sort="Kienene, T" uniqKey="Kienene T" first="T" last="Kienene">T. Kienene</name>
<name sortKey="Tabutoa, K" sort="Tabutoa, K" uniqKey="Tabutoa K" first="K" last="Tabutoa">K. Tabutoa</name>
<name sortKey="Viney, K" sort="Viney, K" uniqKey="Viney K" first="K" last="Viney">K. Viney</name>
</noCountry>
<country name="Nouvelle-Zélande"><noRegion><name sortKey="Hill, P C" sort="Hill, P C" uniqKey="Hill P" first="P C" last="Hill">P C Hill</name>
</noRegion>
</country>
<country name="Suisse"><noRegion><name sortKey="Dye, C" sort="Dye, C" uniqKey="Dye C" first="C" last="Dye">C. Dye</name>
</noRegion>
</country>
<country name="France"><region name="Île-de-France"><name sortKey="Bissell, K" sort="Bissell, K" uniqKey="Bissell K" first="K" last="Bissell">K. Bissell</name>
</region>
<name sortKey="Harries, A D" sort="Harries, A D" uniqKey="Harries A" first="A D" last="Harries">A D Harries</name>
</country>
<country name="Afrique du Sud"><noRegion><name sortKey="Williams, B G" sort="Williams, B G" uniqKey="Williams B" first="B G" last="Williams">B G Williams</name>
</noRegion>
</country>
<country name="Belgique"><noRegion><name sortKey="Zachariah, R" sort="Zachariah, R" uniqKey="Zachariah R" first="R" last="Zachariah">R. Zachariah</name>
</noRegion>
</country>
<country name="Australie"><region name="Nouvelle-Galles du Sud"><name sortKey="Marais, B J" sort="Marais, B J" uniqKey="Marais B" first="B J" last="Marais">B J Marais</name>
</region>
</country>
</tree>
</affiliations>
</record>
Pour manipuler ce document sous Unix (Dilib)
EXPLOR_STEP=$WICRI_ROOT/Wicri/Asie/explor/AustralieFrV1/Data/PubMed/Checkpoint
HfdSelect -h $EXPLOR_STEP/biblio.hfd -nk 003407 | SxmlIndent | more
Ou
HfdSelect -h $EXPLOR_AREA/Data/PubMed/Checkpoint/biblio.hfd -nk 003407 | SxmlIndent | more
Pour mettre un lien sur cette page dans le réseau Wicri
{{Explor lien |wiki= Wicri/Asie |area= AustralieFrV1 |flux= PubMed |étape= Checkpoint |type= RBID |clé= pubmed:25199002 |texte= Mass treatment to eliminate tuberculosis from an island population. }}
Pour générer des pages wiki
HfdIndexSelect -h $EXPLOR_AREA/Data/PubMed/Checkpoint/RBID.i -Sk "pubmed:25199002" \ | HfdSelect -Kh $EXPLOR_AREA/Data/PubMed/Checkpoint/biblio.hfd \ | NlmPubMed2Wicri -a AustralieFrV1
![]() | This area was generated with Dilib version V0.6.33. | ![]() |